NASDAQ:AKCA - Akcea Therapeutics Stock Price, News & Analysis

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Akcea Therapeutics Inc (NASDAQ:AKCA) released its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.02. The business earned $26.62 million during the quarter, compared to analysts' expectations of $25.78 million. Akcea Therapeutics had a negative net margin of 65.62% and a negative return on equity of 43.87%. The business's revenue was up 45.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.85) EPS. View Akcea Therapeutics' Earnings History.

Akcea Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Akcea Therapeutics.

3 analysts have issued 12 month price objectives for Akcea Therapeutics' stock. Their forecasts range from $31.00 to $45.00. On average, they anticipate Akcea Therapeutics' share price to reach $39.6667 in the next twelve months. This suggests a possible upside of 89.3% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.

Press coverage about AKCA stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akcea Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Akcea Therapeutics.

Akcea Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totalling 6,028,700 shares, a decrease of 5.5% from the July 31st total of 6,381,000 shares. Based on an average daily trading volume, of 195,200 shares, the days-to-cover ratio is currently 30.9 days. Approximately 38.7% of the shares of the company are sold short. View Akcea Therapeutics' Current Options Chain.

Some companies that are related to Akcea Therapeutics include Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Beigene (BGNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), FibroGen (FGEN) and Allakos (ALLK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Achaogen (AKAO), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), Apollo Global Management (APO) and Ciena (CIEN).

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

Akcea Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.05%), Vanguard Group Inc. (1.72%), Morgan Stanley (0.24%), Northern Trust Corp (0.21%), Alps Advisors Inc. (0.21%) and Charles Schwab Investment Management Inc. (0.10%). Company insiders that own Akcea Therapeutics stock include Ionis Pharmaceuticals Inc, Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Institutional Ownership Trends for Akcea Therapeutics.

AKCA stock was sold by a variety of institutional investors in the last quarter, including International Biotechnology Trust PLC, Bank of New York Mellon Corp, AQR Capital Management LLC, Zurcher Kantonalbank Zurich Cantonalbank and BNP Paribas Arbitrage SA. Company insiders that have sold Akcea Therapeutics company stock in the last year include Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Insider Buying and Selling for Akcea Therapeutics.

AKCA stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Alps Advisors Inc., Morgan Stanley, Bank of America Corp DE, BlackRock Inc., Renaissance Technologies LLC, GSA Capital Partners LLP and Jefferies Group LLC. View Insider Buying and Selling for Akcea Therapeutics.

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKCA stock can currently be purchased for approximately $20.95.

Akcea Therapeutics has a market capitalization of $1.95 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.View Additional Information About Akcea Therapeutics.

The official website for Akcea Therapeutics is http://www.akceatx.com/.

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]